Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.66 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.66 |
| ▸ | KDM1A | O60341 | 9/20 | 0.53 |
| ▸ | MAOB | P27338 | 6/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9132268 | 0.98 | GRIN1 (0.64) | GRIN1GRIN2AKDM1AMAOBSIGMAR1 | |
| SCHEMBL10277987 | 0.87 | KDM4E (0.58) | GRIN1GRIN2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL10232539 | 0.87 | KDM4E (0.58) | GRIN1GRIN2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL10230682 | 0.87 | KDM4E (0.58) | GRIN1GRIN2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL8446901 | 0.85 | GRIN1 (0.49) | GRIN1GRIN2AKDM1AMAOBSIGMAR1 | |
| SCHEMBL9132271 | 0.83 | GRIN1 (0.61) | GRIN1GRIN2AKDM1AMAOBSIGMAR1 | |
| SCHEMBL354130 | 0.83 | GRIN1 (0.45) | GRIN1GRIN2AKDM1AMAOBALDH1A1 | |
| SCHEMBL9848956 | 0.78 | MTOR (0.57) | KDM1AMAOBALDH1A1 | |
| SCHEMBL7320028 | 0.77 | HRH1 (0.50) | KDM1AMAOBSIGMAR1ALDH1A1 | |
| SCHEMBL9127621 | 0.77 | MTOR (0.55) | KDM1AMAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| EP-1646659-B1 | METHOD FOR THE PREPARATION OF 1,3-PROPANE DISULFONIC ACID COMPOUNDS | KIACTA S RL (CH) | 2014-05-14 | — | — | EP | disclosed |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
| US-8642801-B2 | Methods and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-02-04 | — | — | US | disclosed |
| US-8642801-B2 | Methods and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-02-04 | — | — | US | disclosed |
| EP-1646659-A2 | IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | Neurochem (International) Limited (CH) | 2006-04-19 | — | — | EP | disclosed |
| EP-1644325-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2006-04-12 | — | — | EP | disclosed |
| US-20050143462-A1 | Pharmaceutical drug candidates and methods for preparation thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-06-30 | — | — | US | disclosed |
| US-20050096385-A1 | Methods and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2005-05-05 | — | — | US | disclosed |
| WO-2004113275-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113391-A2 | IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-12-29 | — | — | WO | disclosed |
| US-5422355-A | Also for treating memory impairment, dementia or cerebral insufficiency | JOHN WYETH & BROTHER, LIMITED (GB) | 1995-06-06 | — | — | US | disclosed |
| US-5260331-A | Selective gamma aminobutyric acid autoreceptors; treatment of dementia | JOHN WYETH & BROTHER LIMITED (GB) | 1993-11-09 | — | — | US | disclosed |
| US-5086073-A | Brain disorders | JOHN WYETH & BROTHER LIMITED (GB) | 1992-02-04 | — | — | US | disclosed |
| EP-0407032-A2 | Aromatic and heteroaromatic amines for treating depressions, cerebral insufficiency disorders or dementia | JOHN WYETH & BROTHER LIMITED (GB) | 1991-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143462-A1 | Pharmaceutical drug candidates and methods for preparation thereof | MPST, TTR, STS | GRIN1 3524/4885GRIN2A 4667/4885KDM1A 2776/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | GRIN1 2196/4885GRIN2A 1579/4885KDM1A 4208/4885 |
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | GRIN1 2196/4885GRIN2A 1579/4885KDM1A 4208/4885 |
| US-20050096385-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | GRIN1 2196/4885GRIN2A 1579/4885KDM1A 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.